Fondaparinux

 化学構造式
816468-88-9
CAS番号.
816468-88-9
化学名:
别名:
英語名:
Fondaparinux
英語别名:
Sr 90107;Fondaparinux;Unii-J177fow5jl;Natural heparin pentasaccharide;alpha-D-Glucopyranoside, methyl o-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-o-beta-D-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate)
CBNumber:
CB6975195
化学式:
C31H53N3O49S8
分子量:
1508.26322
MOL File:
816468-88-9.mol

Fondaparinux 物理性質

安全性情報

Fondaparinux 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

Fondaparinux 化学特性,用途語,生産方法

作用機序

The development of fondaparinux, a synthetically derived pentasaccharide that binds specifically to and activates antithrombin III, is a further refinement on the mechanism of action of heparin. Fondaparinus and a related analogue, idraparinux, are specific, indirect inhibitors of activated factor Xa via their activation of antithrombin. Fondaparinux has strategically located sulfonates that bind to antithrombin. Fondaparinux is structurally related to the antithrombotic binding site of heparin. Unlike heparin or LMWHs, however, these inhibitors have no effect on thrombin, because they lack the longer saccharide chains required for binding to thrombin. The highly sulfated heparins exhibit nonselective binding to a number of additional proteins, resulting in decreased bioavailability and significant variation in activity.

薬物動態学

Fondaparinux is administered via subcutaneous injection with a single daily dose and shows complete absorption. The drug is highly bound to antithrombin III (~94%), with no significant binding to other plasma proteins. Because of the predictable anticoagulant effect, the drug does not require routine coagulation monitoring. The drug is not metabolized and is excreted in the urine unchanged within 72 hours in patients with normal renal function. Fondaparinux has an elimination half-life of 17 hours. Presently, no clinically significant drug interactions have been reported.

臨床応用

Fondaparinux is the first selective factor Xa inhibitor that is approved for the prophylaxis of DVT, which may occur in patients undergoing hip fracture surgery or hip or knee replacement surgery (59).

副作用

The most common side effect is major and minor bleeding, and the patient must be carefully monitored. The drug is not to be used when spinal anesthesia or spinal puncture is employed because of the potential for developing a blood clot in the spine. Fondaparinux has not been reported to cause thrombocytopenia, a condition seen with heparin. It is 100% bioavailable, with little or no protein binding.

Fondaparinux 上流と下流の製品情報

原材料

準備製品


Fondaparinux 生産企業

Global( 4)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12338 58

  • 816468-88-9
  • alpha-D-Glucopyranoside, methyl o-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-o-beta-D-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate)
  • Natural heparin pentasaccharide
  • Sr 90107
  • Unii-J177fow5jl
  • Fondaparinux
Copyright 2017 © ChemicalBook. All rights reserved